|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1997-9-9
|
|
pubmed:abstractText |
The ESPAC-1 trial is the largest study of its kind in pancreatic cancer and should definitively address the question of the role of conventional methods of adjuvant treatment in pancreatic cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0169-4197
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
97-104
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9209950-Adenocarcinoma,
pubmed-meshheading:9209950-Adult,
pubmed-meshheading:9209950-Aged,
pubmed-meshheading:9209950-Aged, 80 and over,
pubmed-meshheading:9209950-Chemotherapy, Adjuvant,
pubmed-meshheading:9209950-Clinical Protocols,
pubmed-meshheading:9209950-Combined Modality Therapy,
pubmed-meshheading:9209950-Europe,
pubmed-meshheading:9209950-Female,
pubmed-meshheading:9209950-Fluorouracil,
pubmed-meshheading:9209950-Humans,
pubmed-meshheading:9209950-Leucovorin,
pubmed-meshheading:9209950-Male,
pubmed-meshheading:9209950-Middle Aged,
pubmed-meshheading:9209950-Pancreatic Neoplasms,
pubmed-meshheading:9209950-Radiation-Sensitizing Agents,
pubmed-meshheading:9209950-Radiotherapy, Adjuvant
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Progress report. A randomized multicenter European study comparing adjuvant radiotherapy, 6-mo chemotherapy, and combination therapy vs no-adjuvant treatment in resectable pancreatic cancer (ESPAC-1).
|
|
pubmed:affiliation |
Department of Surgery, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|
